Calliditas Therapeutics AB (publ) (CALT)
Market Cap | 498.61M |
Revenue (ttm) | 105.88M |
Net Income (ttm) | -26.91M |
Shares Out | 26.84M |
EPS (ttm) | -0.98 |
PE Ratio | n/a |
Forward PE | 8.77 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 14,761 |
Open | 18.68 |
Previous Close | 18.27 |
Day's Range | 17.70 - 19.00 |
52-Week Range | 10.82 - 25.64 |
Beta | 1.34 |
Analysts | Strong Buy |
Price Target | 49.00 (+163.72%) |
Earnings Date | Nov 13, 2023 |
About CALT
Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary... [Read more]
Financial Performance
In 2022, CALT's revenue was 802.88 million, an increase of 250.07% compared to the previous year's 229.35 million. Losses were -412.27 million, -17.59% less than in 2021.
Financial numbers in SEK Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for CALT stock is "Strong Buy." The 12-month stock price forecast is $49.0, which is an increase of 163.72% from the latest price.
News

Calliditas Therapeutics to Present Nefecon Data at the 17th International Symposium on IgA Nephropathy (IIgANN) September 25-27 in Tokyo
STOCKHOLM , Sept. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), today announced upcoming data presentations from the NeflgArd Phase 3 Stu...

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy
STOCKHOLM , Aug. 18, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT), (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the U.S. Food and Drug Administration (FDA) has acce...

Interim Report Q2, 2023: Calliditas Therapeutics
Filing for full approval of TARPEYO STOCKHOLM , Aug. 17, 2023 /PRNewswire/ -- FINANCIAL SUMMARY FOR THE GROUP Key Figures April 1 - June 30, 2023 Net sales amounted to SEK 269.4 million, of which TARP...

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet
STOCKHOLM , Aug. 15, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced publication in The Lancet of the full data from the Phase ...

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
STOCKHOLM , July 13, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced interim data from the proof-of-concept Phase 2 trial in pat...

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®
STOCKHOLM , June 21, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced the submission of a supplemental New Drug Application ("sND...

Everest Medicines' Partner Calliditas Therapeutics Makes Data Presentations on Nefecon at European Renal Association - European Dialysis and Transplant Association Congress (ERA-EDTA )
SHANGHAI , June 20, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced today that its partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALT...

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
STOCKHOLM , May 30, 2023 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on 30 May 2023, in Stockholm. Adop...

Calliditas Therapeutics: Interim Report Q1, 2023
STOCKHOLM , May 16, 2023 /PRNewswire/ -- Strong eGFR Data from Positive NefIgArd Phase 3 Trial Readout "In March we announced that the global NefIgArd Phase 3 trial successfully met its primary endpo...

Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023
STOCKHOLM , May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the ...

Notice of annual general meeting of Calliditas Therapeutics AB (publ)
STOCKHOLM, April 28, 2023 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to ...

Calliditas Therapeutics' 2022 Annual Report Published
STOCKHOLM , April 26, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2022 now is available at the company's website:...

Calliditas Announces Publication of Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with IgA Nephropathy in the United States
NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marke...

Calliditas to participate in upcoming investor conferences
STOCKHOLM , March 31, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced its management's participation in the following investor co...

Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy
STOCKHOLM , March 13, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced positive topline results from the global, randomized, doub...

Calliditas - Year-End Report, 2022
2022: Successful transformation into a commercial stage company STOCKHOLM , Feb. 23, 2023 /PRNewswire/ -- "2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approv...

Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy
STOCKHOLM , Feb. 2, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Medicines and Healthcare products Regulatory Agenc...

Number of shares and votes in Calliditas Therapeutics
STOCKHOLM , Jan. 31, 2023 /PRNewswire/ -- During January, Calliditas Therapeutics AB (publ) has issued 7,500 common shares connected to the company's long term incentive program 2019/2022. Thus, as of...

China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy
STOCKHOLM , Dec. 30, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced that the Center for Drug Evaluation (CDE) of the Chi...

Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2019/2022
STOCKHOLM , Dec. 21, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced today that CEO Renée Aguiar-Lucander has net purchased 50,0...

Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan
Calliditas announces that it has entered into an agreement with Viatris to bring Nefecon®, a specialty therapy focused on downregulating IgA1, to Japanese patients. The agreement, worth up to $100M in...

Calliditas to host fireside chat with its China commercial partner, Everest Medicines
STOCKHOLM , Dec. 9, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a fireside chat with its commercial partner Everest Medicines (HKEX 1952.HK...

Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPA
STOCKHOLM , Nov. 15, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Chinese regulatory authority National Medical Prod...

Calliditas Therapeutics: Interim Report Q3, 2022
Conditional Marketing Authorization in EU Granted for Kinpeygo® STOCKHOLM , Nov. 14, 2022 /PRNewswire/ -- "On July 15th the European Commission issued the conditional marketing authorization for Kinpe...

Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape
STOCKHOLM , Nov. 7, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a Key Opinion Leader (KOL) Fireside Chat on the IgA Nephropathy (IgAN) treat...